7 completed, 3 recruiting, 2 active not recruiting, 1 terminated. 14 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 7, Recruiting 3, Active not recruiting 2, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
Follow Axitinib: new trials by email Literature Review of Axitinib trials Research Report on Axitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer Axitinib, Biospecimen Collection, Bone Scan - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 718 | 2026-06-05 | 2026-06-11 |
| CARE1 Pragmatic Clinical Trial Nivolumab, Ipilimumab, Pembrolizumab - Metastatic Kidney Cancer, Metastatic Kidney Carcinoma | Phase 3 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 1250 | 2024-04-12 | 2025-01-16 |
| Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration OTX-TKI (axitinib implant), Aflibercept - Neovascular Age-Related Macular Degeneration | Phase 3 | Active not recruiting | Ocular Therapeutix, Inc. | 344 | 2024-01-29 | 2025-04-18 |
| The Efficacy and Safety of KN046 Combined With Axitinib KN046 plus Axitinib - NSCLC | Phase 2 / Phase 3 | Unknown | Shanghai Pulmonary Hospital, Shanghai, China | 20 | 2023-08-25 | 2023-08-31 |
| Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma Axitinib plus Toripalimab, nephrectomy - Renal Cell Carcinoma, Neoadjuvant | Phase 3 | Recruiting | ZHOU FANGJIAN | 298 | 2023-04-19 | 2026-03-17 |
| Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) fruquintinib+sintilimab, axitinib / everolimus, fruquintinib - Advanced Renal Cell Carcinoma | Phase 2 / Phase 3 | Completed | Hutchmed | 265 | 2022-10-27 | 2026-10-20 |
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Avelumab, Lorlatanib, Talazoparib - Advanced Malignancies, NSCLC | Phase 3 | Active not recruiting | Pfizer | 77 | 2021-09-29 | 2026-10-20 |
| Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) Pembrolizumab, Axitinib, Sunitinib - Renal Cell Carcinoma | Phase 3 | Completed | Merck Sharp & Dohme LLC | 861 | 2016-09-16 | 2026-02-02 |
| A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) Avelumab (MSB0010718C), Axitinib (AG-013736), Sunitinib - Renal Cell Cancer | Phase 3 | Completed | Pfizer | 886 | 2016-03-23 | 2025-07-30 |
| Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients Axitinib, Placebo - Clear Cell Renal Carcinoma | Phase 3 | Terminated | SFJ Pharma Ltd. II | 724 | 2012-04-01 | 2019-09-20 |
| Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas Axitinib, Sandostatin LAR, Placebo - Neuroendocrine Tumors, Advanced Cancer | Phase 2 / Phase 3 | Completed | Grupo Espanol de Tumores Neuroendocrinos | 256 | 2011-11-01 | 2026-04-28 |
| Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer Axitinib (AG-013736), Sorafenib - Kidney Neoplasms | Phase 3 | Completed | Pfizer | 492 | 2009-08-25 | 2022-05-06 |
| Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer Axitinib (AG-013736), Sorafenib - Kidney Neoplasms | Phase 3 | Completed | Pfizer | 723 | 2008-09-03 | 2019-01-09 |
| Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer. AG-013736, Gemcitabine, placebo - Carcinoma, Pancreatic Ductal | Phase 3 | Completed | Pfizer | 630 | 2007-07-01 | 2012-07-16 |
Carcinoma, Renal Cell (6) · Kidney Neoplasms (4) · Carcinoma, Pancreatic Ductal (1) · Clear-cell metastatic renal cell carcinoma (1) · Kidney Diseases (1) · Neoplasms (1) · Neuroendocrine Tumors (1) · Ovarian Neoplasms (1)
Pfizer (5) · Grupo Espanol de Tumores Neuroendocrinos (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Hutchmed (1) · Merck Sharp & Dohme LLC (1) · Ocular Therapeutix, Inc. (1) · SFJ Pharma Ltd. II (1) · SWOG Cancer Research Network (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · ZHOU FANGJIAN (1)
United States (8) · China (6) · France (6) · Spain (6) · Italy (5) · Japan (5) · Russia (5) · South Korea (5) · Taiwan (5) · United Kingdom (5) · Australia (4) · Austria (4) · Canada (4) · Germany (4) · India (4)
Dingwei Ye (1) · Fangjian Zhou, Professor (1) · Pedro Barata (1) · Rocio Garcia Carbonero, MD (1) · Zhi Song He (1)
PMID 37526095, PMID 33947608, PMID 37146227, PMID 27238653, PMID 28410911, PMID 21306953, PMID 22056247, PMID 23579211, PMID 23598172, PMID 23630366, PMID 24206640, PMID 24823696, PMID 25577718, PMID 26089686, PMID 27498023, PMID 29439857, PMID 30346481, PMID 30779529, PMID 30779531, PMID 31072748, PMID 32339648, PMID 32363929, PMID 32895571, PMID 33152282, PMID 33284113, PMID 33901870, PMID 34244116, PMID 35166465, PMID 35239416, PMID 35843776, PMID 37104931, PMID 37852850, PMID 39706335, PMID 39815637, PMID 39886142, PMID 40750932, PMID 41719493
2023 (3), 2008 (1), 2015 (1), 2016 (1), U10CA180888 (1)